Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.

Enikő BárcziViktória VargaAlexandra NagyNoémi EszesZsuzsanna Kovats Veronika Muller Anikó Bohács

Published in: Immunity, inflammation and disease (2022)

Immunosuppression therapy may induce a weaker SARS-CoV-2 response in LuTX recipients; therefore, third dose is a priority in transplanted patients. The highest antibody level was measured recovering from COVID after two doses. Our data confirm that booster mRNA vaccine could increase antibody levels, even if immunization was started with non-mRNA vaccine.

Keyphrases

sars cov
respiratory syndrome coronavirus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
coronavirus disease
electronic health record
patient reported outcomes
bone marrow
artificial intelligence